Citations

Showing 10 of 107852 citations.

Pneumocystis carinii Cell Wall Biosynthesis Kinase Gene CBK1 Is an Environmentally Responsive Gene That Complements Cell Wall Defects of cbk -Deficient Yeast
Kottom, Theodore J. , Limper, Andrew H.

Mayo Clinic

Infection and Immunity | July 23, 2004 | Volume: 72 | Issue: 8 | Pages: 4628-4636

10.1128/iai.72.8.4628-4636.2004 | PMID 15271923 Get It

ABSTRACT Pneumocystis species remain an important cause of life-threatening pneumonia in immunocompromised hosts, including those with AIDS. Responses of the organism to environmental cues both within the lung and elsewhere have been poorly defined. Herein, we report the identification of a cell wall biosynthesis kinase gene ( CBK1 ) homologue in Pneumocystis carinii , isolated by differential display PCR, that is expressed optimally at physiological pH (7 to 8) as opposed to more acidic environments. Expression of Pneumocystis CBK1 was also induced by contact with lung epithelial cells and extracellular matrix. Translation of this gene revealed extensive homology to other fungal CBK1 kinases. Pneumocystis CBK1 expression was equal in the cyst and trophic life forms of the organisms. We further demonstrate that Pneumocystis CBK1 expressed in cbk1Δ Saccharomyces cerevisiae cells restored defective cell wall separation during proliferation. Consistent with this, Pneumocystis CBK1 expression also stimulated transcription of the CTS1 chitinase in cbk1Δ mutant yeast cells, an event necessary for cell wall separation. In addition, Pneumocystis CBK1 cDNA supported normal mating projection formation in response to α-factor in the cbk1Δ yeast cells. Site-directed mutations of serine-303 and threonine-494, potential regulatory phosphorylation sites in Pneumocystis CBK1, abolished mating projection formation, indicating a role for these amino acid residues in CBK1 activity. These findings indicate that Pneumocystis CBK1 is an environmentally responsive gene that may function in signaling pathways necessary for cell growth and mating.
Atypical Tensile-Sided Femoral Neck Stress Fractures
Provencher, Matthew T. , Baldwin, LT Andrew J., Gorman, John D., Gould, Mark, Shin, Alexander Y. , Shin, Alexander Y

Mayo Clinic

The American Journal of Sports Medicine | July 20, 2004 | Volume: 32 | Issue: 6 | Pages: 1528-1534

10.1177/0363546503262195 | PMID 15310582 Get It

The Ideal Nasal Profile
Pearson, David, Adamson, Peter A.

Mayo Clinic

Archives of Facial Plastic Surgery | July 19, 2004 | Volume: 6 | Issue: 4 | Pages: 257-262

10.1001/archfaci.6.4.257 | PMID 15262721 Get It

Forehead Flap Periorbital Reconstruction
Price, Daniel L. , Sherris, David A., Bartley, George B., Garrity, James A., Price, Daniel L

Mayo Clinic

Archives of Facial Plastic Surgery | July 19, 2004 | Volume: 6 | Issue: 4 | Pages: 222-227

10.1001/archfaci.6.4.222 | PMID 15262715 Get It

Micro-Computed Tomography—Current Status and Developments
Ritman, Erik L.

Mayo Clinic

Annual Review of Biomedical Engineering | July 15, 2004 | Volume: 6 | Issue: 1 | Pages: 185-208

10.1146/annurev.bioeng.6.040803.140130 | PMID 15255767 Get It

▪ Abstract The recent rapid increase in interest in tomographic imaging of small animals and of human (and large animal) organ biopsies is driven largely by drug discovery, cancer detection/monitoring, phenotype identification and/or characterization, and development of disease detection methods and monitoring efficacies of drugs in disease treatment. In biomedical applications, micro-computed tomography (CT) scanners can function as scaled-down (i.e., mini) clinical CT scanners that provide a three-dimensional (3-D) image of most, if not the entire, torso of a mouse at image resolution (50–100 μm) scaled proportional to that of a human CT image. Micro-CT scanners, on the other hand, image specimens the size of intact rodent organs at spatial resolutions from cellular (20 μm) down to subcellular dimensions (e.g., 1 μm) and fill the resolution-hiatus between microscope imaging, which resolves individual cells in thin sections of tissue, and mini-CT imaging of intact volumes.
Idiopathic Interstitial Pneumonia
Flaherty, Kevin R. , King, Talmadge E. , Raghu, Ganesh , Lynch, Joseph P., Colby, Thomas V. , Gross, Barry H., Kazerooni, Ella A. , Toews, Galen B., Long, Qi , Murray, Susan , Lama, Vibha N. , Gay, Steven E., Long, Qi , Travis, William D. , Martínez, Fernando J. , Long, Qi

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 15, 2004 | Volume: 170 | Issue: 8 | Pages: 904-910

10.1164/rccm.200402-147oc | PMID 15256390 Get It

Abstract Current guidelines recommend that the clinician, radiologist, and pathologist work together to establish a diagnosis of idiopathic interstitial pneumonia. Three clinicians, two radiologists, and two pathologists reviewed 58 consecutive cases of suspected idiopathic interstitial pneumonia. Each participant was provided information in a sequential manner and was asked to record their diagnostic impression and level of confidence at each step. Interobserver agreement improved from the beginning to the end of the review. After the presentation of histopathologic information, radiologists changed their diagnostic impression more often than did clinicians. In general, as more information was provided the confidence level for a given diagnosis improved, and the diagnoses rendered with a high level of confidence were more likely congruent with the final pathologic consensus diagnosis. The final consensus pathologist diagnosis was idiopathic pulmonary fibrosis in 30 cases. Clinicians identified 75% and radiologists identified 48% of these cases before presentation of the histopathologic information. Histopathologic information has the greatest impact on the final diagnosis, especially when the initial clinical/radiographic diagnosis is not idiopathic pulmonary fibrosis. We conclude that dynamic interactions between clinicians, radiologists, and pathologists improve interobserver agreement and diagnostic confidence.
Randomized Phase II Study of Two Irinotecan Schedules for Patients With Metastatic Breast Cancer Refractory to an Anthracycline, a Taxane, or Both
Perez, Edith A. , Mailliard, James A., Ryan, J. Michael, Fitch, Tom R., Rowland, Kendrith M. , Kardinal, Carl G., Krook, James E., Kugler, John W., Dakhil, Shaker R. , Hillman, David W. , Ingle, James N.

Mayo Clinic

Journal of Clinical Oncology | July 14, 2004 | Volume: 22 | Issue: 14 | Pages: 2849-2855

10.1200/jco.2004.10.047 | PMID 15254052 Get It

Purpose A pressing need exists for agents active against anthracycline- or taxane-refractory metastatic breast cancer (MBC), or both. Previous clinical trials suggested that irinotecan might have such activity. We conducted this multicenter phase II study to assess efficacy and tolerability of two irinotecan schedules. Patients and Methods MBC patients who experienced disease progression after one to three chemotherapy regimens, including at least one anthracycline- or taxane-based regimen, were randomly assigned to irinotecan in 6-week cycles comprising 100 mg/m2 weekly for 4 weeks, then a 2-week rest (weekly) or 240 mg/m2 every 3 weeks. Results The weekly arm had 52 assessable patients; the every-3-weeks arm had 51 assessable patients. In the weekly arm, the objective response (complete regression [CR] + partial regression [PR]) rate was 23% (one CR, 11 PR; 95% CI, 13% to 37%). Median response duration was 4.9 months (range, 1.9 to 15.9 months), and median overall survival was 9.7 months (95% CI, 8.0 to 14.2 months). In the every-3-weeks arm, the objective response rate was 14% (nine PR; 95% CI, 6% to 26%), median response duration was 4.2 months (range, 3.1 to 13.9 months), and median overall survival was 8.6 months (95% CI, 7.0 to 12.3 months). Treatment generally was well tolerated, especially in the weekly arm. Grade 3 to 4 adverse events with ≥ 10% incidence included neutropenia (29%) and diarrhea (17%) in the weekly arm and neutropenia (36%), vomiting (20%), dyspnea (18%), nausea (16%), and diarrhea (12%) in the every-3-weeks arm. Conclusion Irinotecan is active with good tolerability in refractory MBC. Irinotecan (especially weekly) warrants additional study as monotherapy and in combination regimens in this setting.
Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Benson, Al B. , Catalano, Robert B., Engelking, Constance, Martenson, James A., McCallum, Richard W. , Mitchell, Edith P. , O’Dorisio, Thomas M. , Wadler, Scott, Ajani, Jaffer A. , Kornblau, Steven M. , Vokes, Everett E.

Mayo Clinic

Journal of Clinical Oncology | July 14, 2004 | Volume: 22 | Issue: 14 | Pages: 2918-2926

10.1200/jco.2004.04.132 | PMID 15254061 Get It

Purpose To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea. Methods An expert multidisciplinary panel was convened to review the recent literature and discuss recommendations for updating the practice guidelines previously published by this group in the Journal of Clinical Oncology in 1998. MEDLINE searches were performed and the relevant literature published since 1998 was reviewed by all panel members. The treatment recommendations and algorithm were revised by panel consensus. Results A recent review of early toxic deaths occurring in two National Cancer Institute-sponsored cooperative group trials of irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer has led to the recognition of a life-threatening gastrointestinal syndrome and highlighted the need for vigilant monitoring and aggressive therapy for this serious complication. Loperamide remains the standard therapy for uncomplicated cases. However, the revised guidelines reflect the need for recognition of the early warning signs of complicated cases of diarrhea and the need for early and aggressive management, including the addition of antibiotics. Management of radiation-induced diarrhea is similar but may not require hospitalization, and chronic low- to intermediate-grade symptoms can be managed with continued loperamide. Conclusion With vigilant monitoring and aggressive therapy for cancer treatment-induced diarrhea, particularly in patients with early warning signs of severe complications, morbidity and mortality may be reduced.
Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric Carcinoma
Mansfield, Paul F. , Janjan, Nora A., Morris, Jeffrey S. , Pisters, Peter W. T., Lynch, Patrick M. , Feig, Barry W. , Myerson, Robert J., Nivers, R., Cohen, Deborah S., Gunderson, Leonard L., Ajani, Jaffer A.

Mayo Clinic

Journal of Clinical Oncology | July 14, 2004 | Volume: 22 | Issue: 14 | Pages: 2774-2780

10.1200/jco.2004.01.015 | PMID 15254045 Get It

Purpose In the West, curative (R0) resection is achieved in approximately 50% of patients with localized gastric carcinoma, and more than 60% die of cancer following an R0 resection. A multi-institutional study of preoperative chemoradiotherapy was done to assess the R0 resection rate, pathologic complete response (pathCR) rate, safety, and survival in patients with resectable gastric carcinoma. Patients and Methods Operable patients with localized gastric adenocarcinoma were eligible. Staging also included a laparoscopy and endoscopic ultrasonography (EUS). Patients received up to two 28-day cycles of induction chemotherapy of fluorouracil, leucovorin, and cisplatin, followed by 45 Gy of radiation plus concurrent fluorouracil. Patients were then staged and surgery was attempted. Results Thirty-four patients were registered at three institutions. One ineligible patient was excluded. Most patients had a promixal cancer and EUST3N1 designation. Twenty-eight (85%) of 33 patients underwent surgery. The R0 resection rate was 70% and pathCR rate was 30%. A pathologic partial response (< 10% residual carcinoma in the primary) occurred in eight patients (24%). EUS T plus N and postsurgery T plus N correlation showed significant downstaging (P = < .01). The median survival time for 33 patients was 33.7 months. Patients achieving a pathCR or pathPR had a significantly longer median survival time (63.9 months) than those achieving less than pathPR (12.6 months; P = .03). There were two treatment-related deaths. Conclusion Our data suggest that the three-step strategy of preoperative induction chemotherapy followed by chemoradiotherapy resulted in substantial pathologic response that resulted in durable survival time. This strategy is worthy of a direct comparison with postoperative adjuvant chemoradiotherapy.
Canine Distemper Virus and Measles Virus Fusion Glycoprotein Trimers: Partial Membrane-Proximal Ectodomain Cleavage Enhances Function
Messling, Veronika von , Devaux, Patricia , Cattaneo, Roberto , Milošević, Dragana

Mayo Clinic

Journal of Virology | July 14, 2004 | Volume: 78 | Issue: 15 | Pages: 7894-7903

10.1128/jvi.78.15.7894-7903.2004 | PMID 15254162 Get It

ABSTRACT The trimeric fusion (F) glycoproteins of morbilliviruses are activated by furin cleavage of the precursor F 0 into the F 1 and F 2 subunits. Here we show that an additional membrane-proximal cleavage occurs and modulates F protein function. We initially observed that the ectodomain of approximately one in three measles virus (MV) F proteins is cleaved proximal to the membrane. Processing occurs after cleavage activation of the precursor F 0 into the F 1 and F 2 subunits, producing F 1a and F 1b fragments that are incorporated in viral particles. We also detected the F 1b fragment, including the transmembrane domain and cytoplasmic tail, in cells expressing the canine distemper virus (CDV) or mumps virus F protein. Six membrane-proximal amino acids are necessary for efficient CDV F 1a/b cleavage. These six amino acids can be exchanged with the corresponding MV F protein residues of different sequence without compromising function. Thus, structural elements of different sequence are functionally exchangeable. Finally, we showed that the alteration of a block of membrane-proximal amino acids results in diminished fusion activity in the context of a recombinant CDV. We envisage that selective loss of the membrane anchor in the external subunits of circularly arranged F protein trimers may disengage them from pulling the membrane centrifugally, thereby facilitating fusion pore formation.